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SUMMARY 
South Africa is one of the high burden countries for TB in Sub Sahara in Africa with 
Mpumalanga as one of the provinces with a high burden of disease. Data available on 
tuberculosis in Msukaligwa indicate the following: Cure Rate 40%; Smear conversion at the end 
of intensive phase 35% and Defaulter Rate 27.5%. 
The problem of TB is made worse by the twin epidemic of HIV, with a prevalence of 38.9% in 
our district -the highest among the 3 districts in the province. Retreatment TB carries the risk of 
developing TB drug resistance with severe consequences for the patient and the population. 
Understanding the characteristics of these patients will help in designing  interventions to 
prevent the problem, promote a high cure rate for patients with TB in our health care system  
and reduce to minimum the burden of re-treatment pulmonary TB  on our health care facilities 
and community. One critical precondition for Retreatment TB is non adherence to TB treatment. 
Factors responsible for non adherence could be classified as individual patient factors; Co-
morbid conditions; Health system; treatment related and Community factors. The outcomes of 
Retreatment TB could be, cure, and death and failure of treatment leading to drug resistance.     
The Setting of this study is the 58-bedded TB hospital in Ermelo. The Aim of the study was to 
describe the occurrence, characteristics and management outcome of Retreatment Pulmonary 
Tuberculosis in patients in the Ermelo TB hospital. The specific Objectives were to describe the 
socio-demographic, behavioural and clinical factors related to recurrence of the TB in patients; 
to determine the contribution of non adherence to treatment on recurrence of TB in the study 
population; to identify the prevalence of resistance to TB medication among patients with 
Retreatment TB ; to identify treatment outcomes in patients who have been followed up for the 
duration of Retreatment TB and finally to make recommendations to the Department of Health, 
Mpumalanga towards minimizing Retreatment TB and improving the overall TB programme. 
The Study design is cross sectional and descriptive; the study population comprised of patients 
admitted with TB at Ermelo TB hospital aged 15 years and older between 1 January 2005 and 
31 December 2007.No specific probability sampling was applied in the selection of the patients. 
Data Collection involved visits to the TB hospital during the period and extracting the relevant 
information from the patient medical records and the TB register using a predesigned data 
collection form. Data analysis was done by the statistician from the Centre for Statistical 
Consultation, University of Stellenbosch. Being a descriptive study, the data analysis expresses 
the prevalence of various factors associated with retreatment TB. This study met the Ethical 
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approval of the University of Stellenbosch as well as the Research Ethics Committee of the 
Department of Health & Social Services, Mpumalanga. 
Findings 
All the three hundred and eighty eight patient records with retreatment TB forming 19.6% of TB 
patients admitted between 2005 and 2007 were reviewed. The distributions of the patients were: 
males 66%; mean age of 41.4 years; females 34%; mean age 35.3 years. They were mostly 
unemployed; primary education 93%; unmarried 43% and married 34%.Retreatment TB was 
diagnosed with sputum smear microscopy in 71% with bacilli load of 3+ in 45%.The sources of 
referral to TB hospital were: public hospital 71 %; private doctors 2%. 74% of the patients have 
had TB 1-3 years before the episode under study. Retreatment TB categories were: after 
treatment completed 69%; default 19%; after cure 8% and treatment failure 4%. 98% of patients 
tested had +ve HIV status; the median CD4 cell count was 106 cells/µl at the time of 
retreatment; very few (5%) were on ART. Drug resistance to primary TB drugs was as follows: 
Rifampicin 16%; Isoniazid 29%; Ethambutol 19% and Streptomycin 23%. The treatment 
outcomes for those whom data were available were: successful 49.1%, death 23.8%; treatment 
default 22.9%.   MDR-TB complicated 3.3% of the patients.  
Conclusion: Majority of the retreatment TB patients were males with an average age of 
41years and unemployed. More than two thirds of the patient had completed TB treatment 
previously and default on treatment accounted for less than one quarter of retreatment 
categories. The process of care was better in terms of diagnosis of TB with sputum smear. 
Improvement in the documentation of key factors like smoking, alcohol, drug use among 
patients and co-morbidity as well as counselling and testing for HIV and provision of ARTs is 
required. Treatment outcomes with regards to successful outcome need to be monitored and 
improved upon.  
 
 
 INTRODUCTION and BACKGROUND  
Tuberculosis (TB) is a major public health problem worldwide and since 1993 the WHO1 has 
proclaimed it as a public health emergency. South Africa is one of the high burden countries for 
TB with a very high annual estimated incidence2. In the Mpumalanga province of South Africa, 
the burden of tuberculosis reflects the national trend. The incidence of TB in our municipal area 
is estimated as second highest in the district at about 450/100,0003. Other health indicators 
available for tuberculosis in Msukaligwa municipal area indicate a serious problem with the 
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following for 2006: Cure Rate 40%; Smear conversion at the end of intensive phase 35% and 
Defaulter Rate 27.5%3 
The TB problem is worsened by the twin epidemic of HIV disease with the prevalence of HIV 
(38.9%) in our district being the highest (National Dept of Health, 2006 survey).Improper 
treatment and default on treatment could result in TB bacilli developing resistance to treatment 
with dire consequences for the patient and the population. Patients who present with re-
treatment Pulmonary TB represent a group that could eventually lead to development of drug 
resistance. Understanding the characteristics of these patients will help in designing  
interventions that will prevent non adherence to treatment, enhance adherence and  high  cure 
rate for patients with TB in our health care system as well as reduce to minimum the burden of 
re-treatment pulmonary TB  on our health care facilities and community.  
The setting of this study is the TB hospital located in Ermelo, Msukaligwa municipality in Gert 
Sibande district of Mpumalanga. This is one of the 2 TB hospitals in the district with a bed 
capacity for 58 beds; it is a dedicated institution for the admission of adult TB patients. Patients 
are referred from the one regional, 5 district hospitals, primary health care clinics and private 
doctors in the Gert Sibande district for admission at the hospital.  
All Retreatment TB patients who are ill and live far away from the hospital are usually admitted 
for an initial period of 6-8 weeks. During this admission sputa are collected at intervals specified 
in the National TB treatment guidelines and Retreatment regimen commenced. Decisions on the 
continuation of treatment, sputum culture, drug sensitivity and treatment failure are made 
depending on the sputum smear results at these periods. On discharge, patients can be 
reviewed monthly as outpatients in the hospital or followed up at the nearest primary healthcare 
clinics in their area.  All patients who choose to be followed up at the clinics are given letters of 
referral to the clinic sister. Once they are at the clinic they are referred for supervision of 
treatment under DOTS programme and will visit the clinic monthly to collect their medication 
until the treatment is completed. 
LITERATURE   REVIEW 
Retreatment TB occurs within the context of related issues of non- adherence to TB treatment in 
the first instance. The conceptual framework therefore is that non adherence to TB treatment 
leads to continuing illness which is diagnosed by the clinical process, sputum smear and chest 
X-ray as Retreatment TB and then commenced on treatment.  
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According to WHO2 (2007), it is estimated that there were 8.8 million people diagnosed with new 
TB cases in 2004 (136 per 100000), including 3.9 million (60 per100000) new smear positive 
cases. The 2005 estimate puts the incidence of TB in South Africa at 245 cases (200-302) per 
100000 population per year and prevalence at between 344-718 cases/100000 population. It is 
also estimated that mortality due to TB varies between 47-107deaths /100000 populations 
(71/100000); proportion of new adult TB cases 15-49 years that are HIV+ 58% (49-65%); New 
TB cases multidrug resistant 1.8% (1.4-2.3%) and previously treated TB cases that were 
multidrug resistant in 2002 as 6.7% (5.5-8.1%) 2. 
Retreatment Tuberculosis occurs after a person may or may not have completed the scheduled 
treatment course for TB. It can occur due to endogenous reactivation or exogenous re-
infection4,5. In the South African National TB Control Program6 various categories of 
Retreatment TB have been identified. 
A recent systematic review7 found the rates of recurrence of TB after successful treatment to 
vary from 0% to 14 % due to a number of factors that included treatment regimen, presence of 
concomitant diseases. However, they submitted that the observed differences in recurrence 
rates could be explained by the key factors of whether the treatment is taken daily compared 
with intermittently (three times weekly), the characteristics of patients included in the studies, 
and poor treatment adherence  as a result of the difficulties of direct observation of doses. In a 
study among South African mine workers8,it was found that the recurrence rate for TB was 10.3 
episodes per 100 person years at risk during a follow up of the patients for the median period of 
25.1months with most of the recurrence occurring within the first 6 months of follow up.  Another 
study9 found that the rate of recurrence TB was 18 % in the study population with recurrence 
occurring after successful treatment and after default. In those in which DNA finger printing was 
available most recurrences after successful treatment were due to re-infection. The re-infection 
rate after successful treatment was estimated at 2.2 per 100 person years. People with previous 
TB have a four times higher risk of TB compared to TB naïve patients.  
The determination of whether an episode of TB infection is a relapse or reinfection with a new 
TB strain is one of the issues in Retreatment TB. This differentiation can be done using DNA 
finger printing techniques with Mycobacterium TB8, 9,10,11,12, 13, 14 . Whether re-treatment TB in a 
patient is due to re-infection or re-activation is not clinically distinguishable. The mechanisms 
that have been postulated as leading to the development re-treatment TB in patients are either 
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endogenous and true treatment failure or exogenous re-infection. Two separate studies in 
Rwanda10,11 using molecular techniques and DNA finger printing respectively found that 
recurrent TB and treatment failure was not due to re-infection and that most MDR-TB patients 
were found to be related to reactivation and treatment failure.  In an area of low TB incidence 
and low HIV prevalence, studies have revealed that re-infection with new M. tuberculosis strain 
is considered a rare cause of recurrent TB14 .This contradicted the findings in a population- 
based retrospective case- control study15 in Houston, USA, where re-infection with new strain of 
M. Tuberculosis was the cause of recurrent TB. 
 In a setting of high TB and HIV prevalence respectively, as in South Africa the relative 
contribution of re-infection or relapse to recurrent TB is different.  A study10 among South 
African mine workers, found that most recurrent TB was due to relapse within 6 months with re-
infection common in patients with HIV infection. An earlier study in South Africa12 using DNA 
finger printing had shown that re-infection was the cause of recurrence of tuberculosis. Using 
DNA finger printing in a population- based retrospective longitudinal study16 in Spain; 
researchers also found Mycobacterium strains from some patients with episodes of recurrent TB 
indicating relapse in most while the rest suggested re-infection. They concluded that re-infection 
is possible among people in developed countries but at lower rates than those in high risk areas 
of tuberculosis. In an earlier study13 in the same environment, investigators argued that re-
infection plays an important part in recurrent TB in a population without the usual clinical and 
epidemiological characteristics that are assumed to favour it.  
One of the underlying issues predisposing to Retreatment TB is non- adherence which can be 
considered under personal, health system; co- morbid and community related factors.   
A number of individual factors have been known to affect adherence to TB treatment. Several 
studies in Africa and elsewhere 17,18,19,20 have shown that males are more likely to default on TB 
treatment than females who are more likely to have excellent adherence to TB treatment 21,22 . 
However, in a community- based study in Zambia 23, a slightly more females were found to have 
stopped taking their TB medication after they started feeling better. Among other things, the 
study also found that age, marital status were not associated with compliance. While age is 
linked to default on TB treatment, no particular age is singled out. One study found that a 
younger age is associated with increased adherence24. A study from Turkey25 that reported on a 
default rate of 5.1% among patients in one TB center, also stated that a risk factor for non 
successful treatment were patients older than 46 years. Other studies from Nigeria18 found that 
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44.2% who defaulted treatment were older than 65yrs while a study in India20, found that not 
completing the process of diagnosis of TB was higher in >50yrs age.  
Social, economic and behavioural factors play important role in adherence to TB treatment. 
These have been found in studies in Nepal26 and Russia27. The factors identified were 
unemployment, low status occupation, low income, cost of transport to facility and 
homelessness. In yet another study in Brazil 28, it was found that the rate of default on TB 
treatment was 10 times (11.7%) higher in the poorest patients in a study than among the 
wealthiest members of the study population (1.6%). 
Behavioural factors related to smoking, use of alcohol and drug use are known to affect 
outcome of TB treatment. Smoking has been found to be independent predictors of relapse and 
poor adherence to TB treatment and contributed to default on treatment of MDR-TB18,19, 29,30,31,32. 
The associations of Retreatment TB with other diseases  like COPD, chronic bronchitis, peptic 
ulcer, chronic hepatitis and occupational hazards been described by various workers33, 34. In 
most developing countries, particularly in Africa an important co-morbid condition in TB is the 
HIV infection. Many studies in South Africa, Zambia and other parts of Africa 8, 35, 36,37,39,38, have 
highlighted the importance of HIV as a risk factor not only for the re-treatment TB, but also in 
terms of outcomes. In a setting of high risk of TB infection, HIV-1 infection increases the risk of 
recurrent tuberculosis because of the risk of re-infection. Retreatment TB in these patients was 
associated with severe immunosupression as shown by low CD4 counts38.  
The behaviour of healthcare professionals is important for adherence to TB treatment under 
DOTS. An aspect of this behaviour is the quality of communication between the patient and the 
provider about aspects of the disease and treatment expectations. A study has shown that poor 
grade communication between patients and health care professionals were significantly 
associated with non adherence39. A review of patient defaulters by in-depth interviews and 
participant observation40 identified a number of pertinent health system factors that affected 
adherence as inconvenient timing of the clinics, non provision for treatment in event of family 
emergency and inability to deal with complicated cases like alcoholics. In a South African 
study31 on MDR- TB, it was shown that defaulters reported more dissatisfaction with healthcare 
workers attitudes and therefore missed treatment due to this. Disrespectful treatment from the 
health care worker and not being told the reason for receiving treatment for one year by health 
care worker led to their default from treatment31.    
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Medication related factors have been found to be associated with tendency towards recurrent 
TB in patients as well as defaulting on treatment among MDR-TB patients31. A study in 
Uganda41, found that patients treated with Thiacetazone containing regimen were more likely to 
relapse after treatment than those treated with Rifampicin containing regimen because of the 
serious side effects associated with Thiacetazone.  
The possible outcomes in TB treatment are cure, treatment failure and death.  According to 
WHO2, the targets that TB programs should achieve are: a smear positive detection rate of 
70%; a cure rate of 85% and no default on treatment. There have been no specific targets set 
for re-treatment TB. However, considering the seriousness of this problem on public health, the 
target for cure for Retreatment TB should be the same for all new TB naïve cases. Treatment 
outcomes for TB in South Africa are still below the target of 85% set by WHO and many patients 
are lost to follow up: more than 10% of patients had no recorded outcome. According to WHO2, 
the success rate for re-treatment TB by 2005 was 73%. In comparing Retreatment TB with new 
TB patients, three patterns appear.  These are: treatment success rate in Retreatment TB lower 
than for new cases; patients who default from their first treatment tended to default when treated 
again; patients retreated after relapse or failure faired better in completing treatment and finally 
the high death rates for Retreatment patients in Africa region. 
One of the key consequences of non- adherence to TB treatment is drug resistance to TB 
medication. This could be mono, multidrug or extreme drug resistance. While previous TB 
treatment has been indicated as risk factor associated with drug resistant TB42, an earlier study 
in a South African rural health district43, found that previous treatment history for TB was not 
associated with drug resistance. Other factors shown not to be associated with drug resistance 
in that study were age, sex and known HIV status. Reasons for the previous treatment history 
probably not being a risk factor were use of multiple drug regimen, DOTS and high completion 
rates in the treated patients.  
Other studies in the South Africa gold mines44, 45 found that patients with Retreatment TB were 
more likely to have resistance to any TB drug or MDR-TB. The prevalence of HIV infection or 
the level of CD4 cell count has been found not to a significant factor with the primary or acquired 
resistance to TB medication44,45,46.The only predictor for MDR-TB in HIV +ve patients with  
recurrent TB patient is the history of TB and not their HIV status47,48.  
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Appropriate interventions to prevent and minimize the occurrence of Retreatment TB needs to 
be considered in Africa. Initiatives to promote adherence to TB treatment has been designed 
and included in some TB treatment and preventative programmes in various parts of the world. 
A study49 from some regions in Russia identified lack of social support among the reasons for 
default on treatment and proposed collaboration between the TB programmes and social 
organizations as modalities for improving adherence. Similar studies in other places28, 30, 49 , 50 
had also raised the issue of social incentives to promote adherence to treatment and classified 
them into economic, health service support, administrative and habits. They concluded that 
financial incentives for food and transportation subsidies may be required to improve treatment 
compliance among the poorest TB patients, the homeless and drug users in the community. 
This fact was reaffirmed in a randomized clinical trial on incentives to the poor51. While this was 
concerned with adherence to treatment for latent TB infection, it serves to emphasize the role of 
simple, low cost incentives in getting the poor patients to adhere to treatment interventions.     
The AIM of the study is to describe the occurrence, associated factors and management 
outcome of Retreatment Pulmonary Tuberculosis in patients in the Ermelo TB hospital. 
The OBJECTIVES are: 1 To describe the socio-demographic and behavioural characteristics of 
retreatment TB patients in Ermelo TB Hospital. 2. To determine the contribution of non 
adherence to treatment to retreatment TB in the study population. 3. To identify the prevalence 
of resistance to anti TB medication among patients with Retreatment TB in Ermelo. 4 To identify 
treatment outcomes in patients who have been followed up for the duration of Retreatment TB.  
5. To make recommendations to the Department of Health, Mpumalanga towards minimizing 
Retreatment TB and improving the overall TB programme.  
  
METHODOLOGY 
The Study Design is Descriptive. The Study Population   comprised of all patients admitted 
with TB at the TB hospital in Ermelo the 3 year study period. The sample for actual study 
population was all patients aged 15 years and older who have been diagnosed with 
Retreatment TB and commenced on TB treatment between 1 January 2005 and 31 December 
2007. These are patients who have been entered in the hospital-based TB register with medical 
records available in the hospital. Patients excluded were: those with extra pulmonary TB, 
patients with Retreatment TB started on treatment in 2004 and completing in 2005.  
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The required information was extracted from the TB register and patients medical records. All 
the information extracted was entered into the data collection form that was used for each 
identified patient. The data collection form had three digit serial numbers with no patient 
identifiers on it, but could be cross referenced it to the medical record should it be necessary.  
Information for analysis was derived from the data collection form and entered into the 
spreadsheet designed for the analysis.  
The reliability of the data collected was assured by clear definition of the terms and concepts 
relevant to the study. For this, the case definitions as contained in the South African National TB 
control programme guidelines was used. This applied to definitions such as “Retreatment TB”; 
“Retreatment categories”; “treatment outcomes” and “drug resistance”. To ensure the validity of 
the data collected, reference was made to each of the patient’s records to ensure that what is 
reflected in the TB register is as it appeared in the patient’s medical record. 
The Pilot Study consisted of using the data collection form with a few selected patient files and 
TB register. Necessary modification was made to reflect comments and to refine the form as a 
better data collection tool. The Procedure for data collection involved visits to the Ermelo TB 
hospital during the period of the data collection. The total number of patients treated over the 
study period was ascertained from TB register and patients with Retreatment TB identified. 
From the patients identified in the TB register, the medical records were requested in order to 
extract detailed information about the patient based on the data collection tool developed for this 
purpose.  
The Data analysis was done by Prof M. Kidd from the Centre for Statistical Consultation; 
University of Stellenbosch.  The statistician was contacted from the early stage of the study and 
during the data collection. The data collection form was sent to the statistician who designed the 
spreadsheet on which data on each of the variables contained in the questionnaire was entered 
and subsequently analyzed. Being a descriptive study, the data analysis expresses the 
prevalence of various factors associated with retreatment TB using summary statistics. The data 
is presented mainly in the form of histogram chart reflecting the variables of interest to the 
study. 
DEFINITIONS 
The focus of the study is mainly on Pulmonary Tuberculosis. The diagnosis of tuberculosis was 
considered to be based on any of the following: microscopy- sputum smear and standard 
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reporting of the bacilli load; clinical evaluation of the patient (history: symptoms and signs of 
illness; examination) and chest radiography interpretation. In addition any patient with TB on 
treatment with Regimen 2 was considered to have Retreatment TB and in the absence of any 
documentation this was be taken as Pulmonary TB.  
In order to facilitate the collection of the required data all the definitions applied to the study 
were those defined in the South African TB Control Programme Practical Guidelines 20006.  
ETHICAL CONSIDERATIONS   
Relevant guidelines and laws of South Africa pertaining to health research were adhered to. 
Adequate ethical considerations were made with regards to the following: Protecting the 
interests of the research participants; confidentiality of personal information and freedom to 
draw own conclusions and publish the research findings. The interest of the patients was 
protected by ensuring that the information obtained was not linked to the patients. As a 
retrospective study with data collection by record review, there was no direct patient interaction, 
hence no informed consent was necessary from the patients to use their records.  
The confidentiality of the patient information was safeguarded and respected by keeping the 
medical records safe and inaccessible to others who were not directly involved with the study. 
All the activities of the study did not bring any harm to the patients whose records was reviewed 
or disadvantaged them in any way with regards to future timely access to care in the TB 
hospital. 
It is an expectation that the findings of this study will be published through presentation at 
relevant conferences and publication in medical journals in order to share the research findings 
with others and enrich our understanding of issues associated with Retreatment TB.  
This research was submitted to the Committee for Human Research at the University of 
Stellenbosch for approval which was granted. It was also approved by the Research Ethics 
Committee of the Department of Health, Mpumalanga. 
  
RESULTS 
A total of 388 patients with Retreatment TB were seen at the TB Hospital between 2005 and 
December 2007.These constituted 19.6% of the total 1980 patients treated for TB during the 
period. Males were 66 % while the females were 34%; male: female ratio of 1.9: 1.The mean 
age for the males was 41.4years while for the female it was 35.3 years. For each of gender the 
most affected age group was 35–44 years for male and 25-234 years for females.  The men 
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were older than the females. Ninety three percent (93%) had primary education; 2% high school 
and 6% no formal education and 92.7% were unemployed /blue collar workers. Information on 
social habits: smoking, alcohol and drug use was not known for 98% of the patients. With 
regards to marital status, (43%) were unmarried; in 23 % the marital status was not known;34 % 
were reported as married. On the number of people in the same household excluding the 
patient at the time of the episode of retreatment TB treatment, majority (72%) of the patients 
lived in households with least 2 persons. Majority (97%) of the patients has had TB once in the 
past years and for these 74% had TB in the past 1-3yrs before the episode under study. 
Information on co- morbid conditions were very limited to make logical interpretation as it was 
both 1% for Diabetes and Epilepsy and 0% for COPD and hypertension. Drug resistance to 
primary TB drugs was as follows: Rifampicin 16%; Isoniazid 29%; Ethambutol 19% and 
Streptomycin 23%.  In terms of treatment outcome, successful outcome was 49.1% (cured and 
completed treatment) failure 4.2%; default 22.9% and death 23.8% among those who were 
followed up at the TB hospital. MDR-TB resulted from 3.3% (7/214) of the patients followed up 
in the hospital. 
Figure 1 shows the combined age distribution of the patients in the study. 
Figure 2 shows the distribution of the retreatment TB patients by gender.   
Figure 3 shows the bacilli load in patients diagnosed with sputum microscopy. 
Figure 4 shows how the patient was referred to TB hospital. 
Table 1   shows the distribution of the patients by two broad occupational groups 
Table 2 shows the main diagnostic tool for the TB, in the retreatment TB patients. “Other 
means” - included the use of Pleural fluid ADA. 
 Table 3 shows the Retreatment TB categories based on the previous TB episode. 
Table 4 shows the information on drug sensitivity testing pattern for the primary TB drugs.  On 
the whole, records were available for analysis for about 25.9% (100/386) of the patients. Slightly 
more patients were resistant to Isoniazid compared to Rifampicin. 
 
Table 5 shows the “Treatment Outcomes” for the retreatment TB. MDR-TB is included in the 
Failures. It is a serious complication of retreatment TB and not a   treatment outcome. 
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Fig. 1 Age distribution of the Retreatment TB Patients 
Histogram of Age
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Fig 2 Age distribution by Sex of Retreatment TB patients 
Histogram of Age; categorized by Sex
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 Table 1.  Distribution by Occupation of Retreatment TB Patients  
   OCCUPATIONAL  GROUP  NUMBER OF PATIENTS (%) 
Unemployed /Blue- collar ( laborer , unskilled)  360        ( 92.7) 
Employed / White-collar  ( salaried 
professional educated workers 
28            ( 7.2 ) 
 
 
 
Table 2. Distribution of Retreatment TB patients by How TB was first Diagnosed 
Main Diagnostic tool Number of Patients (%) 
Sputum AFB 276               (71.1) 
Chest X-Ray 93                 (23.9) 
Others 19                  (4.9) 
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Fig.3 Distribution of Retreatment TB patients by Bacilli load  
Histogram of Bacil l i  load
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Fig. 4 Referral Source of Retreatment TB   Patients   
Histogram of How was the patient referred 
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Table 3.  Distribution of Retreatment TB patients by Re-treatment TB category              
                                              (Based on previous TB episode) 
              Re-treatment TB Category  No of Patients (%) 
After treatment completed 266  (69) 
After cure 31      (8) 
After default 75      (19) 
After failure 16       (4) 
 
Fig. 5, 6 and 7 show HIV-related factors. In Fig 5, 98 %( 169/172) patients who were tested and 
results known had +ve results while 3 (1.7%) were -ve.  
Figure 6 shows the distribution of the CD4 count.  The median CD4 count is 106 cells/µl. 
Figure 7 shows the distribution of patients on ART.  Within the period of this study, the roll out of 
ART within the public sector was just beginning within the district. 
Fig. 5 Distribution of Retreatment TB Patients by HIV status  
Histogram of HIV status
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Fig. 6 Distribution of Retreatment TB Patients by CD4 count 
Histogram of CD4 count
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Fig. 7 Distribution of Retreatment TB Patients by ART 
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Table 4. Distribution of Retreatment TB patients by Drug Sensitivity Testing profile 
Drug Total no. of 
patients 
No. of 
patients not 
tested 
No. of 
patients 
tested 
Sensitive (%) Resistant (%) 
Rifampicin 386 286 100 84   (84.0) 16 (16.0) 
Isoniazid 387 287 100 71  (71.0) 29 ( 29.0) 
Ethambutol 387 288 99 80  (80.8) 19 ( 19.1) 
Streptomycin 387 288 99 76   (76.7) 23 (23.2) 
 
Table 5.  Distribution of Retreatment TB Patients by Treatment Outcome for 
patients followed up at the hospital (n= 214)             
TREATMENT    OUTCOME NUMBER OF PATIENTS    (%) 
CURED 19                              (8.9) 
COMPLETED TREATMENT 86                              ( 40.2) 
FAILURE* 9                                ( 4.2) 
DEFAULTED 49                              ( 22.9) 
DEATH 51                               (23.8) 
* Includes patients with MDR- TB (n=7) MDR-TB rate of 3.3%. 
One hundred and seventy one patients 44% (171/388) were transferred to the clinics and 
records were not available for review. 
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DISCUSSION 
Summary of the main Findings 
All the three hundred and eighty eight patient records with retreatment TB were reviewed. This 
was 19.6% of TB patients admitted between 2005 and 2007.The distributions of the patients 
were: males 66%; mean age of 41.4 years; females 34%; mean age 35.3 years. 92.7% were  
unemployed/blue-collar workers; primary education 93%; unmarried 43% and married 
34%.Retreatment TB was diagnosed with sputum smear microscopy in 71% with bacilli load of 
3+ in 45%.The sources of referral to TB hospital were: public hospital 71 %; private doctors 2%. 
74% of the patients have had TB 1-3 years before the episode under study. Retreatment TB 
categories were: after treatment completed 69%; default 19%; after cure 8% and treatment 
failure 4%. 98 %( 169/172) of patients tested had +ve HIV status; the median CD4 cell count 
was 106 cells/µl at the time of retreatment; very few (5%) were on ART. Drug resistance to 
primary TB drugs was as follows: Rifampicin 4%; Isoniazid 7%; Ethambutol 5%% and 
Streptomycin 6%. The treatment outcomes for those whom data were available were: 
successful 49.1%( 107/214) (cured + completed treatment); death 23.8%; treatment default 
22.9% and failure 4.2%. MDR-TB resulted from 3.3% (7/214) of the patients followed up in the 
hospital. 
Comparison to the Literature 
Although the proportion may not directly estimate the extent of retreatment TB in the population, 
it, however, gives some indication of the burden of this problem on the health system within the 
context of already high prevalence of TB and HIV diseases in the community. It reflects a fair 
measure of the load of TB patients that the health care workers and the institution have to cope 
with.The extent of retreatment TB have been estimated to vary from 0 to 14 % after successful 
treatment while a study among South African miners found a rate of 10.3 episodes per 100 
person years at risk during a follow up of patients for the median period of 25.1 months7,8,9 with 
most recurrence occurring within the first 6 months of follow up of patients. This study found that 
74% of patients had TB 1- 3 years before the current episode which compares with the Malawi52 
study that found 60% having another episode of TB within the first 2 years of completing 
treatment. 
The study also revealed some personal factors associated with retreatment TB among the 
patients studied. Most of the patients with retreatment TB were men with a mean age of 41.4 
years compared to women who were relatively younger at an average age of 35.3 years. The 
mean age of females was at least 6.1years less than that of males. While there have not been 
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consistent finding on the effect of gender and default from TB treatment, most studies had 
shown that males are more likely to default TB treatment than females. This may partly explain 
the relative large proportion of males with retreatment TB in this study. The finding of this study 
with regards to males is similar to others that have been reported from studies in Turkey, 
Nigeria and India. In the Turkey study25, the risk factors for non successful treatment were 
determined to be re-treatment patients older than 46 years of age while in the Nigerian study18,  
the 44.2% who defaulted treatment were older than 65 years and in India20, not completing the 
process of diagnosis of TB was higher in >50 years age.  
The prevalence of behavioural and social factors like unemployment, smoking, alcohol and drug 
use in patients with retreatment TB has also emerged from the study. Seventy five per cent of 
the study population indicated being unemployed at the time of treatment. This is the only factor 
that the study was able to pick up and compares well with what has been reported in studies in 
other parts of the world like Nepal, Russia and Brazil 26,27,28 .There was little data on smoking, 
alcohol and drugs use as it was not  documented in the records. This is an important omission 
in the process of care of these patients which should be remedied realizing that there is some 
linkage between these social habits and retreatment TB. 
There was some limited information on the HIV status of the patients with retreatment TB. 
Information on the HIV status was only available for only 44% of the patients. In this study, 
among those who were tested data indicate that 98% were HIV +ve. Previous study34 among 
miners in South Africa has shown that HIV infection was associated with significantly increased 
rates of recurrent TB with an incidence of 8.2 per 100 person-years in HIV positive compared to 
2.2 per 100 person-years in HIV negative men. The need to test patients is recognized in the 
hospital; however, patients can decline after voluntary counseling.   
Another HIV-related factor to the recurrence of TB is the level of immunocompromise as 
reflected by the CD4 counts. Information on this was available on a very small number of 
patients. Other studies53,54 have showed that the risk of developing recurrent TB is increased as 
the immunity worsens with declining CD4 counts. In this study, the median CD4 count for those 
that were available was low at 106cells/µl. The use of ART has been very low in the study 
patient population. This is not unexpected as the roll out of ART in public sector was only 
initiated within the period of the study hence most of those HIV positive patients at that time did 
not have access to such services.  
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The study also shows some information on drug sensitivity patterns amongst patients.  There is 
large proportion of non documentation relating to drug resistance and sensitivity to TB drugs 
used as data was only available for 25.9%( 100/386) of the patients studied. The  low proportion 
of sensitivity testing reflects the  non rigorous attention  to this aspect of care process for the TB 
patients  with regards  to documentation in the patient files. The drug resistance to primary TB 
drugs varied from 16% for Rifampicin to 23% for Isoniazid. Some bacteria isolates in the 
patients showed some dual resistance to Rifampicin and Isoniazid -a criterion for diagnosis 
MDR-TB. Previous TB treatment is an obvious risk factor for drug resistance. The significance 
of this resistance is in the emergence of Multi-drug resistance TB which is an important and 
serious unsuccessful outcome of retreatment TB.  
The outcomes of retreatment TB in this study is only for those who were seen at the TB hospital 
and followed up on discharge. Those who defaulted treatment were those who were followed up 
as out patient in the Hospital after the initial phase of treatment. According to WHO2, the targets 
of TB programs for new PTB patients are smear positive detection rate of 70% and a cure rate 
of 85%. While no specific targets for the outcomes have been set for retreatment TB, all 
indications are that they should not be less than for new TB cases. In terms of the smear 
positive detection rate, the management of TB programme at the hospital has performed  well 
as it  achieved 71% comparing with the WHO set target of 70%, as the TB patients were mostly 
diagnosed with sputum smear microscopy. The treatment outcomes (cured and completed 
treatment) together were found to be 49.1%. This is much less than the 73 % reported by WHO 
in its 2005 global review of TB programmes. Of great significance is the 3.3% MDR-TB found in 
this study. The MDR–TB is very expensive to treat and longer treatment duration which makes it 
difficult for patients to adhere to treatment. This proportion does not, however, derive from the 
estimated proportion of TB cases that were treated during the period which will make the overall 
proportion low. Among new TB cases in South Africa, previous studies had shown the MDR-TB 
rate to be relatively low at 1.6%, while that for retreatment TB was 6.6 %( 4.0-13.9%)31 . When 
compared with this, our figure of 3.3% for the retreatment TB cases is relatively small. However, 
this should be seen against the setting that about 44% of the retreatment TB patients were 
transferred out to other facilities for which information on outcome was not available. 
 Limitations of the study 
The study is limited by its design which is mainly descriptive and retrospective in nature. The 
study relies on the previously collected data and information on the patient file for analysis.  
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Some of the information was incomplete thus making it difficult to have a complete perspective 
of the problem under study. In situations where the diagnosis of TB was based on the chest 
radiograph, this information was accepted as it was recorded and the study did not seek to look 
at the chest radiograph in question. The treatment outcomes of patient discharged from the TB 
hospital and followed up at the clinics were not ascertained due to limited resources to visit the 
clinics. 
The study is further limited by the fact that there is no control or comparison group on which to 
make in-depth analytical appraisal of the identified related factors of retreatment TB. Time and 
resources had made this not possible. This aspect should be explored in future study on this 
problem. 
RECOMMENDATIONS 
1. All TB patients (new or retreatment TB) should be consistently offered voluntary 
counseling and testing for HIV. Those who are HIV positive should be enrolled into ART 
programme and monitored regularly to detect any deterioration in immune status by 
regular CD4 measurement and necessary intervention started. 
2. Improve process of care by appropriate and complete documentation in the patient file of 
all potential factors impacting on retreatment TB at the time of admission into the 
treatment programme and any new developments reviewed and updated as situations 
develop in the patients over the period of care. This will provide sufficient data on which 
the burden of the problem could be understood and allow dominant factors identified to 
be addressed with relevant interventions. Strengthening the institutional capacity to do 
this will be required in terms of personnel and other resources for monitoring and 
reporting on outcomes for retreatment TB patients.  
3. Further researches that involve data collection from the patients directly using 
quantitative and qualitative approaches to allow for quantitative analysis of factors and 
test associations with retreatment TB. 
CONCLUSION 
This study has confirmed some factors related to retreatment TB to be similar to what obtains 
elsewhere. Specifically in our situation majority of patients had completed TB treatment 
previously and default occurred in less than one quarter of the patients. For those tested for HIV 
they were overwhelmingly positive. There is need to improve the quality of care for these 
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patients by paying attention and documenting these factors. This study opens up areas of 
further research in our setting to test associations and prominence of some of the identified 
factors.  
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Appendix   1   : DATA COLLECTION SHEET  
 
TOPIC:    A description of patients with Recurrence of Pulmonary TB in                 
                TB Hospital, Ermelo. 
 
STUDY NUMBER                        
1. Age (years) 
           15-24 
            25-34 
            35 - 44 
            45 - 54 
            55 - 64 
            ≥ 65 
2. Sex                         
M              F 
3. Occupation 
       Unemployed 
       Self employed 
       General Worker/Farm Labourer 
        Teaching/Scholar 
        Administrative/Clerical/Sales 
       Professional/Technical/Mine worker 
4.  Habits  
        Smoking 
        Alcohol 
        Other drug use (dagga, etc) 
        Not Known 
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5.  Education 
       No formal education 
        Primary school    
        High School 
        Tertiary  
        Other (specify) _______________________________________ 
6.  Marital status 
        Married  
         Unmarried 
          Divorced 
          Separated 
             Not Known 
7.  Number of people in the same Household  
   1- 2 
         3- 6 
        Above 6 
         Not Available 
8.   How was TB first diagnosed? 
        Sputum AFB microscopy 
        Chest X-ray  
        Clinical features 
        Others (specify) TB Culture, Pleural Biopsy, ADA, CSF  
9.   Sputum smear result 
 Positive 
 Negative 
          Not Applicable 
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10.  Bacilli load 
       + + + 
        ++ 
        + /scanty 
          Not Applicable 
11. How was the patient referred with Retreatment TB to the TB HOSPITAL? 
           Self 
- Primary care clinic 
 
Public Hospital 
Private Doctor/Private hospital 
           Others ________________________( Specify) 
12.  How many times has the patient had TB in the past?            
            Specify years_______________________ 
13.  Interval since last TB treatment 
               < 1yr               1-3yrs                    4-6yrs                 7- 9yrs             ≥ 10yrs 
14.  Re-treatment TB category 
         Re-treatment after failure of previous treatment (Sputum smear +ve ).            
         Re-treatment after default (interruption of treatment for > 2 months).   
         Re-treatment after cure or (smear result negative at end of treatment). 
        Re-treatment after treatment completed (no sputum smear result). 
        Chronic case – sputum is positive at end of re-treatment. 
15.  HIV status     
        + ve 
         -ve 
            Not Known      
16.  If Positive, what was the CD4 count       
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17.   Is the patient on ART? 
       Yes 
        No 
18.  Indicate the TB Drug sensitivity Testing pattern.       
Item                                                    DRUG  
Rifampicin    Isoniazid   Ethambutol  Streptomycin  Pyrazinamide   
Sensitive/Susceptible      
Resistant      
Not done      
19.  Treatment Outcome  
        Cured (Finished treatment with negative sputum smear) 
         Completed treatment (no sputum result) 
         Failure (sputum still positive at 6 months despite adherence to treatment) 
         Defaulted/Interrupted treatment for 2 months or more 
          Death 
          Transfer /Moved out 
          MDR - TB 
20.  Other associated conditions 
       Diabetes mellitus 
         Hypertension  
        Epilepsy 
        COPD 
        Other_________________________________ (specify) 
21. COMMENTS 
 
 
  
